Remove subscribe
article thumbnail

GoodRx reports spike in drug discount subscribers driving 43% revenue growth in Q2

Fierce Healthcare

GoodRx reports spike in drug discount subscribers driving 43% revenue growth in Q2. Thu, 08/19/2021 - 12:39.

134
134
article thumbnail

“A Cause You Can Subscribe To”

PioneerRx

For the millions of Americans who depend on insulin to live, its immense cost can be a deadly issue. Even with insurance, some patients are still resorting to.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

22 Best Medical Podcasts to Subscribe to in 2023

Board Vitals - Pharmacist

The post 22 Best Medical Podcasts to Subscribe to in 2023 appeared first on BoardVitals Blog. Listening to these is a great way to take a break when you have been studying or seeing patients for a while, or just when you need some entertainment.

article thumbnail

STAT+: Taking stock of the frenzied push into autoimmune disease

STAT

This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox. Good morning! This is a magical time of the year in Boston, with trees in full bloom. I  I want to hear from you!

100
100
article thumbnail

STAT+: Profiting from ‘legal’ insider trading isn’t always easy

STAT

This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox. Last night, we held our 2024 STATUS List dinner, honoring  50 influential people shaping the future of health, medicine and life sciences.

93
article thumbnail

STAT+: Weed for weight loss, and more from Biotech Land

STAT

This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox. Bankruptcies, restructurings, clinical trial setbacks, and falling stock prices: It’s been a disconcerting week in Biotech Land.

105
105
article thumbnail

STAT+: The inside story of Enhertu’s pan-tumor approval

STAT

This is the online edition of Adam’s Biotech Scorecard, a new subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered every Thursday to their inbox. Good morning! The first quarter was the fourth-best quarter for biotech financing on record, according to Jefferies.

101
101